Figure 2.
Disposition of patients in the phase II study by Novotna et al. [2011].
A total of 660 patients with multiple sclerosis were screened and 572 enrolled into a single-blind phase during which all patients received nabiximols; 538 patients completed 4 weeks of treatment. All responders (n = 241) were randomised into a second double-blind phase, during which 124 patients received nabiximols and 117 placebo.